Results 11 to 20 of about 2,242,189 (260)
Overexpression of COL11A1 confers tamoxifen resistance in breast cancer [PDF]
npj Breast CancerBreast cancer is the most commonly diagnosed malignancy and benefits from endocrine agents such as tamoxifen. However, the development of drug resistance in cancerous cells often leads to recurrence, thus limiting the therapeutic benefit.
Chengxiao Fu +4 more
doaj +2 more sources
Microarray analysis of tamoxifen resistance in breast cancer. [PDF]
, 2009 PhDTamoxifen remains a widely used hormone therapy for pre and postmenopausal women with hormone receptor positive breast cancer in both adjuvant and metastatic disease settings. Resistance to this well tolerated and cost-effective drug limits its use.
Moss, Charlotte
core +4 more sources
Frontiers in Oncology, 2022 Acquired resistance is a major clinical challenge for tamoxifen-based therapy. In this study, we focused on lncRNA SNHG6 which plays a role in chemoresistance of cancer cells, but has never been investigated in the context of tamoxifen resistance.
Mohammad Imran Khan +2 more
doaj +1 more source
Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine [PDF]
Integrative Cancer Therapies, 2021 Background: Tamoxifen is one of the medicines for adjuvant endocrine therapy of hormone-dependent breast cancer. However, development of resistance to tamoxifen occurs inevitably during treatment. This study aimed to determine whether sensitivity of tamoxifen-resistant breast cancer cells (TAM-R) could be ...
Yuntao Wang +5 more
openaire +3 more sources
Molecular gene expression and genome wide profiling in tamoxifen-resistant breast cancer. [PDF]
, 2010 PhDOestrogen receptor positive (ER+) breast cancers (BC) are heterogeneous in both their clinical behaviour and response to therapy. The ER and Progesterone (PgR) are currently the best predictors of response to the anti-oestrogen tamoxifen, yet up to 40%
Yeoh, Chit Cheng
core +4 more sources
Mechanisms of tamoxifen resistance [PDF]
Endocrine-Related Cancer, 2004 Abstract The anti-oestrogen tamoxifen is the most commonly used treatment for patients with oestrogen-receptor (ER)-positive breast cancer. Although many patients benefit from tamoxifen in the adjuvant and metastatic settings, resistance is an important clinical problem. The target of tamoxifen in vivo is the ER.
Alistair, Ring, Mitch, Dowsett
openaire +2 more sources
Pathways to tamoxifen resistance [PDF]
Cancer Letters, 2007 Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer. While these approaches have proven to be beneficial to a large number of patients, both de novo and acquired resistance to these drugs is a significant problem.
Rebecca B, Riggins +3 more
openaire +2 more sources
NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
Cells, 2021 Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic ...
Yu Cheon Kim +3 more
doaj +1 more source
Clonal selection in tamoxifen resistance [PDF]
Cancer Biology & Therapy, 2010 Commentary to:MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivityEuphemia Leung, Nagarajan Kannan, Geoffrey W. Krissansen, Michael P.
Kideok, Jin, Saraswati, Sukumar
openaire +2 more sources
Tamoxifen: Mechanisms of Resistance [PDF]
, 2017 The role of estrogen in breast cancer has been recognized for decades. The selective estrogen receptor modulator tamoxifen was the first targeted therapy for the treatment of breast cancer. It was also the first drug approved by the FDA for the reduction
Adams, Cyrus McCoy
openaire +2 more sources